A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of
alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid
endometrial cancers by estimating the objective response rate (ORR). Treatment will continue
until either unacceptable toxicity, progression of disease, or investigator/patient request
for withdrawal.